Enanta (ENTA) director Lesley Russell receives stock options on 20,000 shares

Rhea-AI Filing Summary

Enanta Pharmaceuticals director Lesley Russell received a stock option grant for 20,000 shares of Common Stock. The option has an exercise price of $14.17 per share and expires on March 11, 2036. It vests in substantially equal monthly installments over one year starting on March 11, 2026, with the final installment vesting before the 2027 annual meeting of stockholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Lesley

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.17	03/11/2026		A		20,000		(1)	03/11/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

	/s/ Matthew Kowalsky as attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Enanta Pharmaceuticals (ENTA) report for Lesley Russell?

Enanta Pharmaceuticals reported that director Lesley Russell received a stock option grant for 20,000 shares of Common Stock. This is a compensation-related award, not an open-market purchase or sale, and gives the right to buy shares at a fixed exercise price.

What are the key terms of Lesley Russell’s 20,000-share stock option at ENTA?

The option covers 20,000 shares of Enanta Pharmaceuticals Common Stock at an exercise price of $14.17 per share. It was granted on March 11, 2026 and expires on March 11, 2036, providing a long-term right to buy shares at that price.

How does the Enanta (ENTA) stock option granted to Lesley Russell vest?

The 20,000-share option vests in substantially equal monthly installments over one year starting March 11, 2026. The final monthly installment will vest no later than the nearest Nasdaq Global Select Market trading day before the 2027 annual stockholders’ meeting.

Is Lesley Russell’s Form 4 transaction in ENTA a stock purchase or a grant?

The Form 4 for Enanta Pharmaceuticals shows a grant of a stock option, not an open-market stock purchase. The transaction code is “A,” meaning a grant or award, giving a right to buy 20,000 shares at a $14.17 exercise price if exercised later.

How many Enanta (ENTA) derivative securities does Lesley Russell hold after this transaction?

After the reported Form 4 transaction, Lesley Russell holds 20,000 stock options directly. These options each relate to one share of Enanta Pharmaceuticals Common Stock and collectively represent her reported derivative position following this grant event.